Nasdaq
7 articles
Bluerock Acquisition II IPO Pricing: $150 Million, Trust at $10.05
Bluerock Acquisition Corp. II priced a $150 million SPAC IPO on Nasdaq that closed at $172.5 million, with a $10.05-a-unit trust and a 21-month deadline.
Electra Therapeutics IPO Pricing: $350 Million at $15 a Share
Electra Therapeutics priced 23.3 million shares at $15 in its September 2026 Nasdaq IPO. Our review of the 424B4 prospectus, pipeline, losses and cash.
Inflection Point VIII IPO Pricing: $287.5 Million on Nasdaq
Inflection Point Acquisition Corp. VIII priced a SPAC IPO at $10 a unit on Nasdaq and, with the over-allotment exercised in full, raised $287.5 million.
NorthStrive Acquisition IPO Pricing: $100 Million, Nasdaq
NorthStrive Acquisition Corp I priced a $100 million SPAC IPO at $10 a unit on Nasdaq and put the full amount in trust, with a 12-month window plus extensions.
OceanLight Acquisition IPO Pricing: $100 Million on Nasdaq
OceanLight Acquisition Corp priced a $100 million SPAC IPO at $10 a unit on Nasdaq, with rights and warrants in each unit and a closing 8-K detailing the sale.
Kardigan IPO Pricing: $400 Million Raised at $16 a Share
Cardiovascular biotech Kardigan priced 25 million shares at $16 in its June 2026 Nasdaq IPO. Our 424B4 review covers proceeds, pipeline, losses and cash.
Cerebras IPO Pricing Review: $185 a Share in the 424B4 Prospectus
Cerebras Systems priced 30 million Class A shares at $185 in its May 2026 IPO, raising $5.55 billion on Nasdaq. Our review of the final 424B4 prospectus.